Skip to main content
Clinical Trials/NCT00280085
NCT00280085TerminatedNot Applicable

Pancreatic Beta-Cell Mass And Function Quantification By Means Of Perfusion Imaging

Pfizer2 sites in 1 country29 target enrollmentStarted: December 1, 2005Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Pfizer
Enrollment
29
Locations
2
Primary Endpoint
Pancreatic perfusion

Study Overview

Brief Summary

Assess pancreatic beta cell function using MR imaging.

Detailed Description

The study was terminated on July 31st, 2007. The study was discontinued, as we have not met the primary end point, differentiation between normal volunteers and subjects with type 1 diabetes mellitus. There were no safety concerns.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Normal Volunteers
  • T1DM and T2DM subjects

Exclusion Criteria

  • Concomitant severe conditions

Outcomes

Primary Outcomes

Pancreatic perfusion

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Pfizer
Sponsor Class
Industry

Study Sites (2)

Loading locations...

Similar Trials

The Aim is to Estimate the Total Amount of... | Clinical Trial